Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation | MicrobiomeTrials← Back to trialsNCT03318939
Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
TERMINATEDPHASE2INTERVENTIONAL
Trial Details
Start: 2017-10-11Est. Completion: 2023-04-03
Enrollment target: 648 participants Locations- Mayo Clinic Hospital, Phoenix, Arizona, United States
- Oncology Physician's Network Inc./OPN Healthcare, Arcadia, California, United States
- City of Hope, Duarte, California, United States
- UCSD -Moores Cancer Center, La Jolla, California, United States
- Pacific Shores Medical Group, Long Beach, California, United States
- Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States
- USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
- UC Davis Comprehensive Cancer Center, Sacramento, California, United States
- UCSF Helen Diller Comprehensive Cancer Center at Mt Zion, San Francisco, California, United States
- UCLA Hematology/Oncology, Santa Monica, California, United States
- The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
- Kaiser Permanente Medical Center, Vallejo, California, United States
- Rocky Mountain Cancer Center, Boulder, Colorado, United States
- Yale University, Yale Cancer Center Smilow Cancer Hospital at Yale, New Haven, Connecticut, United States
Other microbiome trials you might be interested in
Malignant Neoplasm
Researchers want to learn if using a study medicine called MK-1084 can help treat NSCLC. MK-1084 is a type of treatment …
Clermont, United StatesEst. completion Jan 14, 2033
Cell Lung CancerSleep Disorders
This exploratory study will identify and characterise disorders frequently reported by patients as contributing to or al…
Strasbourg, FranceCompleted Mar 25, 2025
Georgetown University Medical Center, Washington D.C., District of Columbia, United StatesFlorida Hospital, Orlando, Florida, United StatesH. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United StatesThe Bond & Steele Clinic, P.A. dba Bond Clinic, P.A., Winter Haven, Florida, United StatesUniversity Cancer & Blood Center, LLC, Athens, Georgia, United StatesCTCA - Southeastern Regional Medical Center, Newnan, Georgia, United StatesCTCA - Midwestern Regional Medical Center, Zion, Illinois, United StatesJohns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United StatesMassachusetts General Hospital, Boston, Massachusetts, United StatesKarmanos Cancer Institute, Detroit, Michigan, United StatesMinnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United StatesMayo Clinic, Rochester, Minnesota, United StatesHattiesburg Clinic Hematology/Oncology, Hattiesburg, Mississippi, United StatesRoswell Park Cancer Institute, Buffalo, New York, United StatesNYU Langone Medical Center, New York, New York, United StatesWeill Cornell Medical College, New York, New York, United StatesNorth Shore Hematology Oncology Associates P.C. DBA NY Cancer and Blood Specialists, Port Jefferson Station, New York, United StatesMontefiore Einstein Medical Center for Cancer Care, The Bronx, New York, United StatesNorth Shore Hematology Oncology Associates DBA New York Cancer and Blood Specialists, The Bronx, New York, United StatesDuke University Medical Center, Durham, North Carolina, United StatesCleveland Clinic, Cleveland, Ohio, United StatesThe Ohio State University, Columbus, Ohio, United StatesOklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, United StatesCTCA - Eastern Regional Medical Center, Philadelphia, Pennsylvania, United StatesBaptist Cancer Center, Memphis, Tennessee, United StatesTexas Oncology- Austin, Austin, Texas, United StatesMD Anderson Cancer Center, Houston, Texas, United StatesVirginia Cancer Specialists, PC, Fairfax, Virginia, United StatesSeattle Cancer Care Alliance, Seattle, Washington, United StatesSaint Luc University Hospital, Brussels, BelgiumUniversity Hospitals Leuven, Leuven, BelgiumAmbroise Pare University Hospital Center, Mons, BelgiumGeneral Hospital Delta, Roeselare, BelgiumCross Cancer Institute, Edmonton, Alberta, CanadaBC Cancer - Vancouver, Vancouver, British Columbia, CanadaLondon Regional Cancer Program, London, Ontario, CanadaPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaHopital Larrey, CHU Toulouse, Unité d'Oncologie des Voies Respiratoires, Toulouse, FranceGustave Roussy Oncology Institute, Department of Medical Oncology, Villejuif, FranceSoroka Medical Center, Beersheba, IsraelRambam Healthcare Campus, Haifa, IsraelHadassah Medical Center, Jerusalem, IsraelRabin Medical Center, Petah Tikva, IsraelNational Cancer Institute, IRCCS, Department of Medical Oncology, Milan, ItalySanta Maria delle Croci Hospital, Ravenna, ItalyNational Cancer Institute Regina Elena, IRCCS, Operative Unit of Medical Oncology A 1, Rome, ItalyErasmus Medical Center, Rotterdam, NetherlandsUniversity Hospital Germans Trias i Pujol, Department of Medical Oncology, Barcelona, SpainUniversity Hospital 12 de Octubre, Madrid, Spain